Press release
United Therapeutics Corporation Reports Third Quarter 2022 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today
About this update from United Therapeutics Corporation
[{"type":"text","content":" SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2022. Total revenues in the third quarter of 2022 grew 16% year-over-year to $516.0 million, compared to $444.7 million in the third quarter of 2021.\n\n“We are thrilled to report the highest quarterly revenue in our history,” said Martine Rothblatt, Ph.D., Chairperson and CEO of United Therapeutics. “On top of our historic performance, we continue to innovate with the recent launch of the pivotal TETON 2 study of Tyvaso in idiopathic pulmonary fibrosis, which adds to the four other registration studies we have underway.”\n\n“We are extremely pleased to have achieved several commercial milestones in the third quarter, highlighted by Tyvaso becoming our first $1 billion annual run rate product,” said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. “Tyvaso DPI has provided a catalyst to our growth trajectory and has us well positioned to achieve our goal of 6,000 patients on Tyvaso by the end of the year.”\n\nTHIRD QUARTER 2022 FINANCIAL RESULTS\n\nKey financial highlights include (dollars in millions, except per share data):\n\n\n\n \n\n\n\nThree Months Ended \n\n\nSeptember 30,\n\n\n\n \n\n\n\nDollar\nChange\n\n\n\n \n\n\n\nPercentage\nChange\n\n\n\n\n\n \n\n\n\n \n\n\n\n2022\n\n\n\n \n\n\n\n \n\n\n\n2021\n\n\n\n \n\n\n\n \n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nRevenues\n\n\n\n$\n\n\n\n516.0\n\n\n\n \n\n\n\n$\n\n\n\n444.7\n\n\n\n \n\n\n\n$\n\n\n\n71.3\n\n\n\n \n\n\n\n16 %\n\n\n\n\n\n\nNet income\n\n\n\n$\n\n\n\n239.3\n\n\n\n \n\n\n\n$\n\n\n\n162.7\n\n\n\n \n\n\n\n$\n\n\n\n76.6\n\n\n\n \n\n\n\n47 %\n\n\n\n\n\n\nNet income, per basic share\n\n\n\n$\n\n\n\n5.26\n\n\n\n \n\n\n\n$\n\n\n\n3.62\n\n\n\n \n\n\n\n$\n\n\n\n1.64\n\n\n\n \n\n\n\n45 %\n\n\n\n\n\n\nNet income, per diluted share\n\n\n\n$\n\n\n\n4.91\n\n\n\n \n\n\n\n$\n\n\n\n3.42\n\n\n\n \n\n\n\n$\n\n\n\n1.49\n\n\n\n \n\n\n\n44 %\n\n\n\n\n\nRevenues\n\nThe table below summarizes the components of total revenues (dollars in millions):\n\n\n\n \n\n\n\nThree Months Ended \n\n\nSeptember 30,\n\n\n\n \n\n\n\nDollar\nChange\n\n\n\n \n\n\n\nPercentage\nChange\n\n\n\n\n\n \n\n\n\n \n\n\n\...